For these reasons, NF-κB is often studied as a potential target for the treatment of malignant tumors [37,38,39], including AML [40] for which the therapeutic choice is restricted to few anti-blastic drugs towards which cancer cells develop early resistance. The gene discussed is NFKB1; the disease is acute myeloid leukemia.